Vical (NASDAQ:VICL) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Thursday, ValuEngine reports.
Separately, Zacks Investment Research upgraded Vical from a “hold” rating to a “buy” rating and set a $0.75 price target on the stock in a report on Friday, July 19th.
NASDAQ:VICL traded up $0.05 on Thursday, hitting $0.74. The stock had a trading volume of 283,280 shares, compared to its average volume of 315,282. The company’s fifty day moving average price is $0.79. The company has a market cap of $16.27 million, a P/E ratio of -0.91 and a beta of 0.32. Vical has a 52 week low of $0.66 and a 52 week high of $1.47.
Vical (NASDAQ:VICL) last announced its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.02). Vical had a negative return on equity of 29.46% and a negative net margin of 1,002.10%. As a group, sell-side analysts predict that Vical will post -0.36 EPS for the current fiscal year.
An institutional investor recently bought a new position in Vical stock. Virtu Financial LLC acquired a new position in Vical Incorporated (NASDAQ:VICL) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 121,693 shares of the biotechnology company’s stock, valued at approximately $146,000. Virtu Financial LLC owned about 0.56% of Vical as of its most recent SEC filing. Institutional investors and hedge funds own 33.75% of the company’s stock.
Vical Company Profile
Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company was founded in 1987 and is headquartered in San Diego, California.
Featured Article: What is the price-to-earnings growth (PEG) ratio?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.